

HSV-2 vaccine shows significant clinical symptoms and viral shedding reductions at six months

March 25 2014

Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose. Genocea, a company pioneering novel T cell vaccines and immunotherapies, reported the results from the ongoing trial of GEN-003 today as an oral presentation at the World Vaccine Congress, being held March 24-26 in Washington, DC.

The ongoing Phase 1/2a double-blind, placebo-controlled study showed that patients treated with GEN-003 at the 30 microgram dose level experienced a 72 percent reduction in lesion days six months after study initiation compared to baseline levels (p

Citation: HSV-2 vaccine shows significant clinical symptoms and viral shedding reductions at six months (2014, March 25) retrieved 5 May 2024 from

<https://medicalxpress.com/news/2014-03-hsv-vaccine-significant-clinical-symptoms.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
